183 related articles for article (PubMed ID: 15833928)
1. CYP3A5 genetic polymorphisms in different ethnic populations.
Roy JN; Lajoie J; Zijenah LS; Barama A; Poirier C; Ward BJ; Roger M
Drug Metab Dispos; 2005 Jul; 33(7):884-7. PubMed ID: 15833928
[TBL] [Abstract][Full Text] [Related]
2. Ethnic differences in the distribution of CYP3A5 gene polymorphisms.
Quaranta S; Chevalier D; Allorge D; Lo-Guidice JM; Migot-Nabias F; Kenani A; Imbenotte M; Broly F; Lacarelle B; Lhermitte M
Xenobiotica; 2006 Dec; 36(12):1191-200. PubMed ID: 17162466
[TBL] [Abstract][Full Text] [Related]
3. CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations.
Balram C; Zhou Q; Cheung YB; Lee EJ
Eur J Clin Pharmacol; 2003 Jun; 59(2):123-6. PubMed ID: 12756511
[TBL] [Abstract][Full Text] [Related]
4. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
5. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.
Kuehl P; Zhang J; Lin Y; Lamba J; Assem M; Schuetz J; Watkins PB; Daly A; Wrighton SA; Hall SD; Maurel P; Relling M; Brimer C; Yasuda K; Venkataramanan R; Strom S; Thummel K; Boguski MS; Schuetz E
Nat Genet; 2001 Apr; 27(4):383-91. PubMed ID: 11279519
[TBL] [Abstract][Full Text] [Related]
6. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.
Floyd MD; Gervasini G; Masica AL; Mayo G; George AL; Bhat K; Kim RB; Wilkinson GR
Pharmacogenetics; 2003 Oct; 13(10):595-606. PubMed ID: 14515058
[TBL] [Abstract][Full Text] [Related]
7. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations.
Gervasini G; Vizcaino S; Gasiba C; Carrillo JA; Benitez J
Ther Drug Monit; 2005 Dec; 27(6):819-21. PubMed ID: 16306861
[TBL] [Abstract][Full Text] [Related]
8. CYP3A5 variant allele frequencies in Dutch Caucasians.
van Schaik RH; van der Heiden IP; van den Anker JN; Lindemans J
Clin Chem; 2002 Oct; 48(10):1668-71. PubMed ID: 12324482
[TBL] [Abstract][Full Text] [Related]
9. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population.
Mirghani RA; Sayi J; Aklillu E; Allqvist A; Jande M; Wennerholm A; Eriksen J; Herben VM; Jones BC; Gustafsson LL; Bertilsson L
Pharmacogenet Genomics; 2006 Sep; 16(9):637-45. PubMed ID: 16906018
[TBL] [Abstract][Full Text] [Related]
10. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups.
Lee SJ; Usmani KA; Chanas B; Ghanayem B; Xi T; Hodgson E; Mohrenweiser HW; Goldstein JA
Pharmacogenetics; 2003 Aug; 13(8):461-72. PubMed ID: 12893984
[TBL] [Abstract][Full Text] [Related]
11. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population.
Hu YF; He J; Chen GL; Wang D; Liu ZQ; Zhang C; Duan LF; Zhou HH
Clin Chim Acta; 2005 Mar; 353(1-2):187-92. PubMed ID: 15698606
[TBL] [Abstract][Full Text] [Related]
12. Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil.
Langaee TY; Gong Y; Yarandi HN; Katz DA; Cooper-DeHoff RM; Pepine CJ; Johnson JA
Clin Pharmacol Ther; 2007 Mar; 81(3):386-91. PubMed ID: 17339868
[TBL] [Abstract][Full Text] [Related]
13. Multiplex PCR-pyrosequencing assay for genotyping CYP3A5 polymorphisms.
Aquilante CL; Langaee TY; Anderson PL; Zineh I; Fletcher CV
Clin Chim Acta; 2006 Oct; 372(1-2):195-8. PubMed ID: 16701601
[TBL] [Abstract][Full Text] [Related]
14. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups.
Li D; Zhang GL; Lou YQ; Li Q; Wang X; Bu XY
J Clin Pharm Ther; 2007 Feb; 32(1):89-95. PubMed ID: 17286792
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG
Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181
[TBL] [Abstract][Full Text] [Related]
17. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults.
Givens RC; Lin YS; Dowling AL; Thummel KE; Lamba JK; Schuetz EG; Stewart PW; Watkins PB
J Appl Physiol (1985); 2003 Sep; 95(3):1297-300. PubMed ID: 12754175
[TBL] [Abstract][Full Text] [Related]
18. CYP3A5*3 and CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Central Americans.
Sinues B; Vicente J; Fanlo A; Vasquez P; Medina JC; Mayayo E; Conde B; Arenaz I; Martinez-Jarreta B
Ther Drug Monit; 2007 Aug; 29(4):412-6. PubMed ID: 17667794
[TBL] [Abstract][Full Text] [Related]
19. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam.
Kharasch ED; Walker A; Isoherranen N; Hoffer C; Sheffels P; Thummel K; Whittington D; Ensign D
Clin Pharmacol Ther; 2007 Oct; 82(4):410-26. PubMed ID: 17554244
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population.
Krishnakumar D; Gurusamy U; Dhandapani K; Surendiran A; Baghel R; Kukreti R; Gangadhar R; Prayaga U; Manjunath S; Adithan C
Fundam Clin Pharmacol; 2012 Apr; 26(2):295-306. PubMed ID: 21265876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
